pneumococcal disease prevention
Vaccines · 2018–2022
4decisions
4medicines
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pneumococcal polysaccharide conjugate vaccine, 20-valent Prevention of pneumococcal disease (invasive pneumococcal disease and pneumococcal pneumonia) caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B,… | Nov 2022 | Recommended | input received Lung Foundation Australia |
| pneumococcal polysaccharide conjugate vaccine, 15 valent Prevention of pneumococcal disease in non-Indigenous adults aged ≥70 years, Indigenous adults aged ≥50 years, and individuals at increased risk of pneumococcal… | Nov 2021 | Recommended with restriction | none received |
| pneumococcal conjugate vaccine 13-valent (13vPCV) and pneumococcal polysaccharide vaccine 23-valent (23vPPV) Pneumococcal disease prevention in high-risk populations across all age groups, including healthy older adults, Aboriginal and Torres Strait Islander adults,… | Jul 2019 | Recommended with restriction | unclear |
| pneumococcal polysaccharide conjugate 13-valent Active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and… | Mar 2018 | Noted | input received |
Who spoke
Lung Foundation Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.